


















































































Christian Jung, Bernhard Wernly, Jesper Fjølner, Raphael Romano Bruno, David Dudzinski, Antonio 
Artigas, Bernardo Bollen Pinto, Joerg C. Schefold, Georg Wolff, Malte Kelm, Michael Beil, Sviri Sigal, 
Peter Vernon van Heerden, Wojciech Szczeklik, Miroslaw Czuczwar, Muhammed Elhadi, Michael 
Joannidis, Sandra Oeyen, Tilemachos Zafeiridis, Brian Marsh, Finn H. Andersen, Rui Moreno, Maurizio 
Cecconi, Susannah Leaver, Ariane Boumendil, Dylan W. De Lange, Bertrand Guidet, Hans Flaatten,  




Please cite this article as: Jung C, Wernly B, Fjølner J, et al. Steroid use in elderly critically ill 








This manuscript has recently been accepted for publication in the European Respiratory Journal. It is 
published here in its accepted form prior to copyediting and typesetting by our production team. After 
these production processes are complete and the authors have approved the resulting proofs, the article 





Copyright ©The authors 2021. This version is distributed under the terms of the Creative Commons 
Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact 
permissions@ersnet.org   
 
Steroid use in elderly critically ill COVID-19 patients 
 
Christian Jung (1) Christian.jung@med.uni-duesseldorf.de ,  
Bernhard Wernly (2) b.wernly@salk.at , 
Jesper Fjølner (3) jespfjoe@rm.dk ,  
Raphael Romano Bruno (1) Raphael.Bruno@med.uni-duesseldorf.de ,  
David Dudzinski (4) ddudzinski@mgh.harvard.edu 
Antonio Artigas (5) AArtigas@tauli.cat ,  
Bernardo Bollen Pinto (6) Bernardo.BollenPinto@hcuge.ch ,   
Joerg C. Schefold (7) joerg.schefold@insel.ch ,  
Georg Wolff (1) Georg.wolff@med.uni-duesseldorf.de ,  
Malte Kelm (1) malte.kelm@med.uni-duesseldorf.de ,  
Michael Beil (8) beil@doctors.org.uk ,  
Sviri Sigal (8) Sigals1@hadassah.org.il ,  
Peter Vernon van Heerden (9) vernon@hadassah.org.il ,  
Wojciech Szczeklik (10) wojciech.szczeklik@uj.edu.pl ,  
Miroslaw Czuczwar (11) czuczwarm@gmail.com ,  
Muhammed Elhadi (12) muhammed.elhadi.uot@gmail.com ,  
Michael Joannidis (13) michael.joannidis@tirol-kliniken.at ,  
Sandra Oeyen (14) sandra.oeyen@ugent.be ,  
Tilemachos Zafeiridis (15) tilemachos@hotmail.com ,  
Brian Marsh (16) bmarsh@mater.ie ,  
Finn H. Andersen (17) Finn.H.Andersen@helse-mr.no ,  
Rui Moreno (18) r.moreno@mail.telepac.pt ,  
Maurizio Cecconi (19) maurizio.cecconi@hunimed.eu ,  
Susannah Leaver (20) susannahleaver@nhs.net ,  
Ariane Boumendil (21) ariane.boumendil@gmail.com ,  
Dylan W. De Lange (22) D.W.deLange-3@umcutrecht.nl ,  
Bertrand Guidet (21) bertrand.guidet@aphp.fr ,  
Hans Flaatten (23) Hans.Flaatten@uib.no ,  
COVIP study group (see appendix 1, covip@med.uni-duesseldorf.de )  
 
Affiliations 
1. Heinrich-Heine-University Duesseldorf, Medical Faculty, Department of Cardiology, 
Pulmonology and Vascular Medicine, Duesseldorf, Germany  
2. Department of Anaesthesiology, Perioperative Medicine and Intensive Care Medicine, 
Paracelsus Medical University, Salzburg, Austria 
3. Department of Intensive Care, Aarhus University Hospital, Aarhus, Denmark  
4. Cardiac Intensive Care Unit, Massachusetts General Hospital, Boston, USA 
5. Department of Intensive Care Medicine, CIBER Enfermedades Respiratorias, Corporacion 
Sanitaria Universitaria Parc Tauli, Autonomous University of Barcelona, Sabadell, Spain 
6. Department of Acute Medicine, Geneva University Hospitals, Geneva, Switzerland 
7. Department of Intensive Care Medicine, Inselspital, Universitätsspital, University of Bern, 
Bern, Switzerland 
8. Department of Medical Intensive Care, Hadassah Medical Center and Faculty of 
Medicine, Hebrew University of Jerusalem, Israel 
9. Department of Anesthesia, Intensive Care and Pain Medicine, Hadassah Medical Center 
and Faculty of Medicine, Hebrew University of Jerusalem, Israel 
10. Center for Intensive Care and Perioperative Medicine, Jagiellonian University Medical 
College, Krakow, Poland 
11. 2nd Department of Anesthesiology and Intensive Care, Medical University of Lublin, 
Staszica 16, 20-081, Lublin, Poland 
12. Faculty of Medicine, University of Tripoli, Tripoli, Libya 
13. Division of Intensive Care and Emergency Medicine, Department of Internal Medicine, 
Medical University Innsbruck, Innsbruck, Austria 
14. Department of Intensive Care 1K12IC Ghent University Hospital, Ghent, Belgium 
15. Intensive Care Unit General Hospital of Larissa, Larissa, Greece 
16. Mater Misericordiae University Hospital, Dublin, Ireland 
17. Dep. Of Anaesthesia and Intensive Care, Ålesund Hospital, Ålesund, Norway. Dep. of 
Circulation and medical imaging, Norwegian university of Science and Technology, 
Trondheim, Norway 
18. Unidade de Cuidados Intensivos Neurocríticos e Trauma. Hospital de São José, Centro 
Hospitalar Universitário de Lisboa Central, Faculdade de Ciências Médicas de Lisboa, 
Nova Médical School, Lisbon, Portugal 
19. Department of Anaesthesia IRCCS Instituto Clínico Humanitas, Humanitas University, 
Milan, Italy  
20. General Intensive care, St George´s University Hospitals NHS Foundation trust, London, 
United Kingdom 
21. Sorbonne Universités, UPMC Univ Paris 06, INSERM, UMR_S 1136, Institut Pierre Louis 
d’Epidémiologie et de Santé Publique, Equipe: épidémiologie hospitalière qualité et 
organisation des soins, F-75012, Paris, France. Assistance Publique - Hôpitaux de Paris, 
Hôpital Saint-Antoine, service de réanimation médicale, Paris, F-75012, France 
22. Department of Intensive Care Medicine, University Medical Center, University Utrecht, the 
Netherlands 
23. Department of Clinical Medicine,University of Bergen, Department of Anaestesia and 
Intensive Care, Haukeland University Hospital , Bergen, Norway 
 
Corresponding author: 
Christian Jung, M.D. PhD 
Division of Cardiology, Pulmonology, and Vascular Medicine  
Medical Faculty, University Duesseldorf  






This secondary analysis of the COVIP study shows a higher 30-day-mortality in critically ill 
elderly COVID-19 patients who received steroids as part of their treatment.   
 
Background 
More than a year after the onset of the SARS-Cov-2 pandemic, treating patients with 
COVID-19 remains a challenge. By contrast to the rapid development of effective vaccines 
against SARS-Cov-2, the development of specific and effective therapeutics against COVID-
19 remains largely unresolved. 
In addition to standard intensive care, including oxygen therapy and organ support 
when required, the use of systemic corticosteroids was found to have a positive effect in 
randomised trials. However, data from treating elderly COVID-19 patients are scarce.  
Importantly, treatment with corticosteroids has well documented deleterious effects 
[1]: While the immunosuppressive effect in patients with COVID-19 is presumably 
responsible for the desired therapeutic effect, it may also render the patients more prone to 
secondary bacterial infections and potentially decrease viral clearance [2]. Corticosteroid 
therapy is also associated with hyperglycemia, has catabolic effects and is associated with 
neuropathy. This could potentially affect the risk-benefit balance, especially in vulnerable 
patient groups such as elderly, frail patients.  
Objective 
The aim of this secondary analysis was to investigate the effects of corticosteroid 
therapy in an international observational prospective study of critically ill elderly patients with 
COVID-19.  
Methods  
The COVIP study (“Corona Virus disease (COVID19) in Very Elderly Intensive care 
Patients (VIPs)” - COVIP study (NCT04321265)) included patients aged 70 years or older 
with proven COVID-19 and admitted to an intensive care unit (ICU) [3]. 30-day-mortality was 
defined as the primary endpoint. The study was conducted by the Very old Intensive care 
Patient (VIP) network [4] across 207 ICUs in 35 countries. Data were collected through an 
electronic case report form. A prospective study design was chosen to achieve high-quality 
data. Informed consent was taken if not waived by the local ethical committee.  
Two multi-level logistic regression models were utilised: The first model used the 
hospital unit as random effect and the steroid use as fixed effect. The second model was a 
multi-variable model adjusting for “The Sequential Organ Failure Assessment” (SOFA) score 
and frailty as assessed by the Clinical Frailty Scale (CFS). Sensitivity analyses 





In total, 3082 patients were included in the COVIP study, 2115 patients received 
corticosteroids, and 967 patients received none. Median age was 75 (IQR 72-79] years in 
both groups. With a median SOFA score of 5 (IQR 3-8), there was no difference between the 
two groups. 
30-day mortality was 53% in the group treated with corticosteroids and 42% in the no-
corticosteroid group (p<0.001).  
The univariate 30-day-mortality rates were higher in patients receiving corticosteroids 
(53 vs. 42%; aOR 1.16; 95%CI 1.28-2.02; p<0.001). This association of corticosteroid use 
was even more pronounced after 3 months (69% vs 49%; p<0.001; Figure 1A). In addition, 
we found that corticosteroids remained associated with increased odds of 30-day-mortality 
after multivariable adjustment (aOR 1.60 95%CI 1.26-2.04; <0.001). Further sensitivity 
analyses consistently confirmed the finding in subgroups stratifying for age (Figure 1B. 
<80/≥80 years), frailty (fit/vulnerable/frail), mechanical ventilation (yes/no), non-invasive 
ventilation (yes/no), sex (female/male), symptom onset (≤7days/>7days), and vasopressor 
therapy (yes/no)- Furthermore, in sensitivity analyses evaluating patients in the first surge 
(March-May, aOR 1.38 95%CI 1.05-1.82; p=0.02; n=1448) and the second surge 
(September-December, aOR 2.09 95%CI 1.04-4.21; p=0.04; n=1414) the finding was 
sustained.  
Discussion 
In this prospective study of more than 3000 critically ill COVID-19 patients age 70 
years and older, we have found an independent association of steroid use with increased 
mortality.  
These results question the routine use of corticosteroid treatment in elderly COVID-19 
patients. While the immunosuppressive effect of steroids is undisputed and desirable in the 
context of severe COVID-19 treatment, the adverse effects of steroid treatment in elderly 
patients may outweigh the potential benefits. 
This is the largest prospective analysis of critically ill elderly patients in relation to 
corticosteroid use to treat severe COVID-19 disease. Corticosteroid therapy has been 
established as standard of care in all ICU patients. However, even landmark randomised 
controlled trials do not support this with evidence in elderly patients. The RECOVERY study 
[5] showed no effect of corticosteroids in their subgroup of patients >70 years. Of note, only 
169 patients in this group were on mechanical ventilation.  The CoDEX study found no effect 
 
on mortality after 28 days, but no data was supplied specifically looking at patients above 70 
years old.[6] Thus, both studies included far fewer patients than our current analysis. It is 
important to note that our data does not question the corticosteroid strategy in younger 
COVID-19 patients. It just emphasises that the decision to use corticosteroids needs to be 
individually tailored, first and foremost according to age, but also with regards to 
comorbidities and other factors.[7] 
Our analysis has limitations: First, this is a secondary analysis of a prospective study. 
Second, our study is not randomised and despite multivariable adjustment, it is likely that 
unknown confounding factors may have contributed to our findings. Third, we have no 
detailed information about dosage and duration of corticosteroid treatment.  
In conclusion, in this prospective observational study we found a higher 30-day-
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Figure 1:  
A: Plot of the Kaplan–Meier estimator illustrating survival probability up to 90 days after 
admission to the intensive care unit for patients with and without corticosteroid treatment. 
Log-rank-test: p<0.001. Abbreviations: CI: Confidence interval. d: days 
B: Sensitivity analyses stratifying 30-day-mortality in subgroups for patient-specific 
characteristics and management strategies using multi-level logistic regression models. We 
depicted aORs from the model with the hospital unit as random effect and the steroid use as 
fixed effect. CFS: Clinical frailty scale; NIV: non-invasive ventilation; CI: Confidence interval. 
 
  
 
 
